<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685226</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-CL-00501</org_study_id>
    <nct_id>NCT04685226</nct_id>
  </id_info>
  <brief_title>A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety,&#xD;
      Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Solid Tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To evaluate the safety and tolerability of ICP-723 at different doses in the treatment of advanced solid tumors;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Up to 2 Months</time_frame>
    <description>To determine maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>To preliminarily obtain pharmacokinetic (PK) data of ICP-723 in the treatment of advanced solid tumors include the peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ICP-723</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICP-723</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICP-723</intervention_name>
    <description>ICP-723 is a white, round, uncoated table</description>
    <arm_group_label>ICP-723</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed locallyadvanced malignant solid tumors that are&#xD;
             unresectable or metastatic andthat are unresponsive tostandard treatments or have&#xD;
             relapsed&#xD;
&#xD;
          -  Reported NTRK gene fusion in blood and/or tissueor detected in the specified&#xD;
             laboratory (Phase II only).&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST 1.1.&#xD;
&#xD;
          -  ECOG performance status:&#xD;
&#xD;
               -  Phase I: ECOG performance status of 0-1;&#xD;
&#xD;
               -  Phase II: ECOG performance status of 0-2.&#xD;
&#xD;
          -  Life expectancy more than 3 months.&#xD;
&#xD;
          -  In fertile female subjects or male subjects,duringthe study period to12 weeks after&#xD;
             the last treatment administration,consent to use a medicallyapproved effective&#xD;
             contraception method is required.&#xD;
&#xD;
          -  Participate voluntarily, sign informed consent, and follow the study treatment plan&#xD;
             and scheduled visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received oral fluorouracil chemotherapy within 2 weeks before the first dose of the&#xD;
             study drug; received systemic anti-cancer therapy within 4 weeks or 5 half-livesbefore&#xD;
             the first dose of study drug.&#xD;
&#xD;
          -  Major surgery within 4 weeks or minor surgery within 2 weeks before the first dose of&#xD;
             study drug;invasivediagnostictests are not considered surgery&#xD;
&#xD;
          -  Clinically significant gastrointestinal dysfunction.&#xD;
&#xD;
          -  Known central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease.&#xD;
&#xD;
          -  At the investigator's discretion, evidence of severe or uncontrolled systemic disease&#xD;
&#xD;
          -  Known active hepatitis B, or active hepatitis C, or HIV infection.&#xD;
&#xD;
          -  Has not recovered from toxicity reactions attributable to prior therapy and above&#xD;
             Grade 1&#xD;
&#xD;
          -  Pregnant or lactating women;pregnancy is definedfrom conception to the end of&#xD;
             pregnancy.&#xD;
&#xD;
          -  Has a history of allergic disease, severe drug allergy,and known allergy to any&#xD;
             component of ICP-723 tablets.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rui Hua Xu, MD</last_name>
    <phone>13922296676</phone>
    <email>xurh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Hua XU, MD</last_name>
      <phone>020-87343533</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital Zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nong Xu, MD</last_name>
      <phone>0571-87236114</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

